Guido Parodi1*, MD, PhD; Benedetta Bellandi1, MD; Giuseppe Tarantini2, MD; Fernando Scudiero1, MD; Renato Valenti1, MD; Rossella Marcucci1, MD, PhD; Angela Migliorini1, MD; Niccolò Marchionni1, MD, PhD; Anna Maria Gori1, BS; Chiara Zocchi1, MD; David Antoniucci1, MD
1. Cardiovascular and Thoracic Department, Careggi University Hospital, Florence, Italy; 2. Cardiovascular and Thoracic Department, Padua University, Padua, Italy
Aims: The optimal duration of dual antiplatelet therapy after an acute coronary syndrome (ACS) is still unknown and debated. We sought to assess the incidence of adverse clinical events b
